Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Padron

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Signal Transduction and Targeted Therapy|August 12, 2017
Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancerHarshita B Gupta, Curtis A Clark, Bin Yuan, et al.
Microbiology Spectrum|May 5, 2026
A cocktail of SARS-CoV-2 S stem helix domain and receptor binding domain human monoclonal antibodies prevents the emergence of viral escape mutantsYao Ma, Chengjin Ye, Michael S Piepenbrink, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
A cocktail of SARS-CoV-2 spike stem helix domain and receptor binding domain human monoclonal antibodies prevent the emerge of viral escape mutantsYao Ma, Chengjin Ye, Michael S Piepenbrink, et al.
Cancer Medicine|February 24, 2021
Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapyDeyi Zhang, Ryan M Reyes, Erica Osta, et al.
Journal for Immunotherapy of Cancer|February 9, 2023
Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effectsHaiyan Bai, Alvaro S Padron, Yilun Deng, et al.
Journal for Immunotherapy of Cancer|April 14, 2021
CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activationRyan Michael Reyes, Yilun Deng, Deyi Zhang, et al.
Cancer Research|March 5, 2022
Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic LethalityAnand V R Kornepati, Jacob T Boyd, Clare E Murray, et al.
Molecular Cancer|October 31, 2024
Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitorsClare E Murray, Anand V R Kornepati, Carlos Ontiveros, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Signal Transduction and Targeted Therapy|August 12, 2017
Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancerHarshita B Gupta, Curtis A Clark, Bin Yuan, et al.
Microbiology Spectrum|May 5, 2026
A cocktail of SARS-CoV-2 S stem helix domain and receptor binding domain human monoclonal antibodies prevents the emergence of viral escape mutantsYao Ma, Chengjin Ye, Michael S Piepenbrink, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
A cocktail of SARS-CoV-2 spike stem helix domain and receptor binding domain human monoclonal antibodies prevent the emerge of viral escape mutantsYao Ma, Chengjin Ye, Michael S Piepenbrink, et al.
Cancer Medicine|February 24, 2021
Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapyDeyi Zhang, Ryan M Reyes, Erica Osta, et al.
Journal for Immunotherapy of Cancer|February 9, 2023
Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effectsHaiyan Bai, Alvaro S Padron, Yilun Deng, et al.
Journal for Immunotherapy of Cancer|April 14, 2021
CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activationRyan Michael Reyes, Yilun Deng, Deyi Zhang, et al.
Cancer Research|March 5, 2022
Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic LethalityAnand V R Kornepati, Jacob T Boyd, Clare E Murray, et al.
Molecular Cancer|October 31, 2024
Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitorsClare E Murray, Anand V R Kornepati, Carlos Ontiveros, et al.
Pageof 2